Acadia Pharma (ACAD) Tops Q2 EPS by 11c; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $28.89 -0.07%
Revenue Growth %: +19.1%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: +19.1%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of $0.01, $0.11 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $165.2 million versus the consensus estimate of $163.86 million.
GUIDANCE:
DAYBUE third quarter net sales in the range of $45 to $55 million.
Acadia Pharma sees FY2023 revenue of $530-545 million, versus the consensus of $652.1 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- GitLab Inc (GTLB) Tops Q2 EPS by 7c, Beats on Revenue
- UBS Upgrades InterContinental Hotels Group (IHG:LN) (IHG) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
